Treatment of insomnia in Parkinson's disease: A controlled trial of eszopiclone and placebo
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Parkinson's disease (PD) is a common neurodegenerative disease affecting up to 1 million individuals in the United States. Sleep disturbances, typically in sleep maintenance, are found in up to 88% of these individuals and are associated with a variety of poor outcomes. Despite being common and important, there are few data to guide clinical care. We conducted a 6‐week, randomized, controlled trial of eszopiclone and placebo in 30 patients with PD and insomnia. Patients with other primary sleep disorders (PSG defined) were excluded. The primary outcome was total sleep time (TST), and secondary measures included wake after sleep onset (WASO), number of awakenings, and quality of sleep, among others. The groups did not significantly differ on TST, but significant differences, favoring eszopiclone, did emerge in number of awakenings (P = 0.035), quality of sleep (P = 0.018), and in physician‐rated CGI improvement (P = 0.035). There was also a trend toward significance in WASO (P = 0.071). There were no significant differences between groups in measures of daytime functioning. The drug was well tolerated, with 33% of patients on eszopiclone and 27% of patients on placebo reporting adverse events. Although modest in size, this is the first controlled study of the treatment of insomnia in patients with PD. Eszopiclone did not increase TST significantly but was superior to placebo in improving quality of sleep and some measures of sleep maintenance, which is the most common sleep difficulty experienced by patients with PD. Definitive trials of the treatment of sleep disorders in this population are warranted. © 2010 Movement Disorder Society
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kok, J. S., Berg, I. J., & Scherder, E. J. A. (2013) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000353441 · Cited by 20,589
Validation of the Insomnia Severity Index as an outcome measure for insomnia research
Bastien, C. (2001) · Sleep Medicine · doi:10.1016/s1389-9457(00)00065-4 · Cited by 8,067 · cited 1×
“A variety of secondary endpoints were examined, including wake after sleep onset (WASO), number of awakenings, and the sleep impairment index (SII).(12)”
BackgroundBehavioral and Pharmacological Therapies for Late-Life Insomnia: A Randomized Controlled Trial
Morin, C. M., Colecchi, C., Stone, J., Sood, R., & Brink, D. (1999) · JAMA · doi:10.1001/jama.281.11.991 · Cited by 1,095
Krystal, A. D., Walsh, J. K., Laska, E., Caron, J., Amato, D. A., Wessel, T. C., & Roth, T. (2003) · Sleep · doi:10.1093/sleep/26.7.793 · Cited by 630
SF-36: evaluation of quality of life in severe and mild insomniacs compared with good sleepers
Léger, D., Scheuermaier, K., Philip, P., Paillard, M., & Guilleminault, C. (2001) · Psychosomatic Medicine · doi:10.1097/00006842-200101000-00006 · Cited by 377 · cited 1×
“Insomniacs have been shown to have lower QoL than good sleepers within both healthy and chronically ill populations.(21,22) Treatment trials of insomnia in non-PD populations suggest that improvements in sleep measures are associated with improvements in QoL and daytime functioning,(23,24) but we did not find any diff…”
BackgroundThe meaning of good sleep: a longitudinal study of polysomnography and subjective sleep quality
ÅKERSTEDT, T., HUME, K., MINORS, D., & WATERHOUSE, J. (1994) · Journal of Sleep Research · doi:10.1111/j.1365-2869.1994.tb00122.x · Cited by 298
Nausieda, P. A., Weiner, W. J., Kaplan, L. R., Weber, S., & Klawans, H. L. (1982) · Clinical Neuropharmacology · doi:10.1097/00002826-198205020-00003 · Cited by 245
Walsh, J. K., Krystal, A. D., Amato, D. A., Rubens, R., Caron, J., Wessel, T. C., Schaefer, K., Roach, J., Wallenstein, G., & Roth, T. (2007) · Sleep · doi:10.1093/sleep/30.8.959 · Cited by 239
ROTH, T., WALSH, J., KRYSTAL, A., WESSEL, T., & ROEHRS, T. (2005) · Sleep Medicine · doi:10.1016/j.sleep.2005.06.004 · Cited by 230
Cited by
Seppi, K., Weintraub, D., Coelho, M., Perez‐Lloret, S., Fox, S. H., Katzenschlager, R., Hametner, E., Poewe, W., Rascol, O., Goetz, C. G., et al. (2011) · Movement Disorders · doi:10.1002/mds.23884 · Cited by 1,141
“Menza et al. (2010)90 conducted a 6- week double-blind, parallel-group RCT of eszopiclone versus placebo in 30 (n ¼ 15 eszopiclone, n ¼ 15 placebo) PD patients with insomnia.”
BackgroundParkinson's disease: The quintessential neuropsychiatric disorder
Weintraub, D., & Burn, D. J. (2011) · Movement Disorders · doi:10.1002/mds.23664 · Cited by 423
Chahine, L. M., Amara, A. W., & Videnovic, A. (2017) · Sleep Medicine Reviews · doi:10.1016/j.smrv.2016.08.001 · Cited by 333
Circadian disruption and sleep disorders in neurodegeneration
Shen, Y., Lv, Q.-K., Xie, W.-Y., Gong, S.-Y., Zhuang, S., Liu, J.-Y., Mao, C.-J., & Liu, C.-F. (2023) · Translational Neurodegeneration · doi:10.1186/s40035-023-00340-6 · Cited by 171
Rios Romenets, S., Creti, L., Fichten, C., Bailes, S., Libman, E., Pelletier, A., & Postuma, R. B. (2013) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2013.03.003 · Cited by 166
Metadata
- Authors
- Menza, M., Dobkin, R. D., Marin, H., Gara, M., Bienfait, K., Dicke, A., Comella, C. L., Cantor, C., & Hyer, L.
- Venue
- Movement Disorders
- Publisher
- Wiley
- Published
- 2010-08-15
- Volume
- 25
- Issue
- 11
- Pages
- 1708-1714
- ISSN
- 0885-3185 (ISSN-L)
- 1531-8257
- OpenAlex
- W2089046145
- Cited by
- 109
- References
- 9
- FWCI
- 9.59
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Treatment of insomnia in Parkinson's disease: A controlled trial of eszopiclone and placebo. https://app.cochat.ai/papers/10.1002/mds.23168
- The paper
- Menza, M., Dobkin, R. D., Marin, H., Gara, M., Bienfait, K., Dicke, A., Comella, C. L., Cantor, C., & Hyer, L. (2010). Treatment of insomnia in Parkinson's disease: A controlled trial of eszopiclone and placebo. Movement Disorders. https://doi.org/10.1002/mds.23168
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.